Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 11:45AM ET
17.20
Dollar change
+0.67
Percentage change
4.05
%
IndexRUT P/E- EPS (ttm)-6.56 Insider Own7.11% Shs Outstand21.06M Perf Week17.57%
Market Cap363.95M Forward P/E- EPS next Y-4.99 Insider Trans-2.24% Shs Float19.65M Perf Month20.28%
Income-138.24M PEG- EPS next Q-1.34 Inst Own96.98% Short Float12.26% Perf Quarter78.24%
Sales73.62M P/S4.94 EPS this Y20.26% Inst Trans-2.67% Short Ratio8.76 Perf Half Y49.57%
Book/sh9.07 P/B1.90 EPS next Y1.97% ROA-35.63% Short Interest2.41M Perf Year-55.69%
Cash/sh15.93 P/C1.08 EPS next 5Y- ROE-56.11% 52W Range8.08 - 41.45 Perf YTD82.78%
Dividend Est.- P/FCF- EPS past 5Y- ROI-37.83% 52W High-58.50% Beta0.47
Dividend TTM- Quick Ratio6.25 Sales past 5Y-16.21% Gross Margin96.60% 52W Low112.87% ATR (14)0.90
Dividend Ex-Date- Current Ratio6.25 EPS Y/Y TTM-12.66% Oper. Margin-192.99% RSI (14)69.89 Volatility7.60% 6.15%
Employees145 Debt/Eq1.12 Sales Y/Y TTM-10.32% Profit Margin-187.77% Recom2.38 Target Price20.88
Option/ShortYes / Yes LT Debt/Eq0.90 EPS Q/Q-13.77% Payout- Rel Volume0.81 Prev Close16.53
Sales Surprise-17.97% EPS Surprise-28.87% Sales Q/Q-23.67% EarningsFeb 07 AMC Avg Volume275.21K Price17.20
SMA2015.81% SMA5027.43% SMA20026.95% Trades Volume84,365 Change4.05%
Date Action Analyst Rating Change Price Target Change
Aug-09-23Downgrade JP Morgan Neutral → Underweight $14
Aug-08-23Downgrade Jefferies Buy → Hold $49 → $18
Dec-09-22Initiated H.C. Wainwright Buy $56
Jul-06-22Upgrade Evercore ISI In-line → Outperform $62
Jun-01-22Upgrade Evercore ISI Underperform → In-line $39
Oct-07-21Initiated Jefferies Buy $95
Sep-09-21Initiated SVB Leerink Mkt Perform $55
Jan-29-21Upgrade JP Morgan Underweight → Neutral $55
Nov-24-20Initiated Evercore ISI Underperform $30
Aug-28-20Resumed ROTH Capital Buy $104
Mar-06-24 07:00AM
Feb-08-24 09:07AM
07:08AM
Feb-07-24 05:10PM
04:59PM
04:07PM Loading…
04:07PM
04:01PM
Feb-06-24 07:00AM
Jan-31-24 07:00AM
Jan-05-24 03:09AM
Jan-04-24 07:00AM
Jan-03-24 07:00AM
Dec-16-23 05:01AM
Dec-13-23 09:55AM
Nov-27-23 09:55AM
07:00AM Loading…
Nov-22-23 07:00AM
Nov-21-23 08:46AM
07:18AM
Nov-20-23 04:54PM
04:18PM
04:01PM
Nov-16-23 11:22PM
Nov-13-23 10:00AM
07:00AM
Oct-30-23 10:01AM
Oct-13-23 07:00AM
Sep-17-23 12:00PM
Sep-07-23 07:00AM
Sep-01-23 06:51PM
Aug-31-23 07:00AM
08:08AM Loading…
Aug-13-23 08:08AM
Aug-09-23 01:49PM
Aug-08-23 02:23PM
10:42AM
Aug-07-23 05:15PM
04:07PM
04:01PM
Jul-31-23 07:00AM
Jun-21-23 08:00PM
08:36AM
Jun-20-23 07:00AM
Jun-07-23 07:00AM
May-31-23 07:00AM
May-11-23 05:05AM
May-09-23 07:00AM
May-08-23 05:15PM
04:11PM
04:01PM
04:01PM
May-02-23 04:01PM
Apr-26-23 08:00PM
Apr-25-23 08:01AM
Apr-19-23 09:32AM
Apr-17-23 07:00AM
Apr-06-23 07:00AM
Apr-05-23 07:00AM
Mar-14-23 07:00AM
Mar-08-23 08:51AM
Mar-07-23 07:00AM
Feb-09-23 12:58PM
Feb-08-23 02:13PM
12:57PM
Feb-07-23 05:15PM
04:01PM
07:00AM
Jan-31-23 07:00AM
Jan-06-23 07:00AM
05:29AM
Jan-03-23 07:00AM
Dec-25-22 12:07PM
Nov-23-22 05:09AM
Nov-22-22 07:00AM
Nov-21-22 05:15PM
04:02PM
Nov-14-22 07:00AM
Nov-09-22 07:00AM
Nov-03-22 11:22AM
Oct-19-22 08:00AM
Oct-17-22 07:00AM
Oct-07-22 01:57PM
Oct-03-22 07:00AM
Sep-29-22 07:00AM
Sep-22-22 07:01AM
Sep-07-22 08:30AM
Sep-01-22 07:00AM
Aug-14-22 08:27AM
Aug-11-22 10:55AM
Aug-09-22 12:00AM
Aug-08-22 05:55PM
04:03PM
04:00PM
Aug-02-22 10:00AM
Aug-01-22 07:00AM
Jul-29-22 07:40AM
07:00AM
Jul-28-22 10:03AM
Jul-01-22 09:41AM
Jun-27-22 11:42AM
Jun-24-22 09:03AM
Jun-23-22 10:28AM
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gardiner Nathaniel S.Chief Legal OfficerFeb 26 '24Option Exercise8.995,18746,63175,688Feb 27 06:31 PM
Vance TerryDirectorDec 13 '23Sale9.1215,295139,4905,800Dec 15 08:08 PM
Luly Jay R.President and CEODec 05 '23Sale9.637,23069,625806,793Dec 06 08:17 PM
MELLETT PAUL JSr. VP, Finance & Admin. & CFODec 05 '23Sale9.632,41223,22893,549Dec 06 08:19 PM
Or Yat SunSr. VP, R&D & CSODec 05 '23Sale9.632,41223,228370,695Dec 06 08:22 PM
Gardiner Nathaniel S.Sr. VP & General CounselDec 05 '23Sale9.632,41223,22868,154Dec 06 08:26 PM
Luu BrendanSr. VP, Business Dev.Dec 05 '23Sale9.632,12520,46436,736Dec 06 08:31 PM
Kieffer Tara LynnSr. VP, New Prod. Strat. & DevDec 05 '23Sale9.632,12520,46437,260Dec 06 08:29 PM
Rottinghaus Scott T.Sr. VP & CMODec 05 '23Sale9.635345,14226,466Dec 06 08:24 PM
Gardiner Nathaniel S.Sr. VP & General CounselApr 18 '23Option Exercise30.006,667200,01079,980Apr 19 07:25 PM